Nachrichten zur Myriad Genetics Inc. Aktie

Myriad Genetics (MYGN) Reports Q1 Loss, Misses Revenue Estimates

Myriad (MYGN) delivered earnings and revenue surprises of -56.52% and -1.09%, respectively, for the quarter ended March 2026. Do the…

SOPHiA GENETICS (SOPH) Q4 2025 Earnings Transcript

Image source: The Motley Fool.DATEMarch 3, 2026, 8 a.m. ETCALL PARTICIPANTSChief Executive Officer — Jurgi CamblongChief Financial Officer — George…

Myriad Genetics jumps after Q4 beat; sees Q1 revenue rising 2%–4% Y/Y

…

Myriad Genetics (MYGN) Q4 Earnings and Revenues Surpass Estimates

Myriad (MYGN) delivered earnings and revenue surprises of +350.00% and +1.07%, respectively, for the quarter ended December 2025. Do the…

Myriad Genetics (MYGN) Q4 2025 Earnings Transcript

Image source: The Motley Fool.DATEMonday, Feb. 23, 2026 at 4:30 p.m. ETCALL PARTICIPANTSPresident and Chief Executive Officer — Samraat S.…

After-hours movers: Hims & Hers Health, Keysight, Bed Bath & Beyond, Myriad Genetics, and more

After-hours movers: Hims & Hers Health, Keysight, Bed Bath & Beyond, Myriad Genetics, and more…

Myriad Genetics, Inc. (MYGN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

…

Clairity, Myriad Genetics, and MagView Launch the First Integrated AI and Genetic Risk Platform for Personalized Breast Health

Clairity, Myriad Genetics, and MagView announce a joint collaboration in an effort to identify more women at high risk for…

Myriad Genetics, Inc. (MYGN) Q3 2025 Earnings Call Transcript

…

Myriad Genetics (MYGN) Reports Break-Even Earnings for Q3

Myriad (MYGN) delivered earnings and revenue surprises of +100.00% and +0.24%, respectively, for the quarter ended September 2025. Do the…

Myriad Genetics, Inc. 2025 Q2 - Results - Earnings Call Presentation

…

Myriad Genetics outlines high single-digit to low double-digit growth target through cancer care continuum focus

…

Myriad Genetics, Inc. (MYGN) Q2 2025 Earnings Call Transcript

…

Myriad Genetics (MYGN) Q2 Earnings and Revenues Surpass Estimates

Myriad (MYGN) delivered earnings and revenue surprises of +600.00% and +5.55%, respectively, for the quarter ended June 2025. Do the…

Myriad Genetics, Inc. (MYGN) Q1 2025 Earnings Call Transcript

…

Myriad Genetics (MYGN) Reports Q1 Loss, Misses Revenue Estimates

Myriad (MYGN) delivered earnings and revenue surprises of 40% and 2.03%, respectively, for the quarter ended March 2025. Do the…

Myriad Genetics: Significantly Undervalued With Profitability In Sight

…

Hologic vs. MYGN: Which Molecular Diagnostics Player Has More Upside?

Both HOLX and Myriad Genetics are longstanding key players in the Molecular Diagnostics space. But which one is a better…

Myriad Genetics Announces Inducement Awards

SALT LAKE CITY, April 08, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular…

Myriad Genetics (MYGN) Meets Q4 Earnings Estimates

Myriad (MYGN) delivered earnings and revenue surprises of 0% and 0.22%, respectively, for the quarter ended December 2024. Do the…

Myriad Genetics to Release Fourth Quarter and Full Year 2024 Financial Results on February 24, 2025

Myriad Genetics will hold its fourth quarter and full year 2024 earnings conference call at 4:30 pm ET on Monday,…

MYGN Stock Might Rise on Collaboration With CancerCARE

Myriad Genetics entered into an agreement with CancerCARE for Life to provide individuals within the latters network with access to…

MYGN Stock Gains Following the Launch of Know More Sooner

Myriad Genetics launches an online prenatal genetic testing resource, the Know More Sooner website, to provide comprehensive information about reproductive…

MYGN Stock Gains Following Collaboration With Hannah Storm

Myriad Genetics enters into an agreement with Hannah Storm, who will be the Myriad Genetics Breast Cancer Risk Assessment Program…

Is Myriad Genetics Stock a Smart Hold for Your Portfolio Right Now?

Strategic progress and solid potential in oncology testing keep MYGN on investors radar.…

Myriad Genetics Expands Board of Directors with Election of Mark S. Davis as New Board Member

Myriad Genetics announced the election of Mark S. Davis to its Board of Director, effective immediately, expanding the Board from…

New NCCN Guidelines Boost Myriad Genetics Prolaris: Stock to Gain?

Myriad Genetics Prolaris test reinforced as an Advanced Tool by the NCCN for prognostic assessment.…

Myriad Genetics to Present New Data at San Antonio Breast Cancer Symposium

Myriad Genetics, Inc. announced it will present new data at the 2024 San Antonio Breast Cancer Symposium.…

MYGN Stock Up on Integration of HRD Platform Into Illuminas TSO 500 v2

Myriad Genetics incorporates its proprietary HRD platform in Illuminas updated TruSight Oncology 500 v2 comprehensive gene panel assay.…

MYGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Myriad Genetics, Inc. and Encourages Investors to Contact the Firm

NEW YORK, Nov. 17, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims…

MYGN Stock Might Gain From SneakPeek Availability in Retail Stores

Myriad Genetics announces the availability of SneakPeek - the first at-home early fetal sex test in Walmart, Walgreens and CVS…

Myriad Genetics, Inc. (MYGN) Q3 2024 Earnings Call Transcript

…

MYGN Beats on Q3 Earnings and Revenues, Raises 24 EPS View

Myriad Genetics delivers strong third-quarter results, driven by growth within Pharmacogenomics and Prenatal. The company increases its full-year EPS guidance.…

Myriad Genetics Comments on UnitedHealthcare’s Updated Medical Policy for Pharmacogenetic Testing

Myriad Genetics comments on UnitedHealthcare’s updated medical policy for pharmacogenetic testing…

Should You Continue to Retain MYGN Stock in Your Portfolio?

Myriad Genetics is advancing with strategic priorities, and bringing new products and upgrades to the market, positively influencing investors sentiment.…

Global Gene Panel Market Size To Worth USD 4.46 Billion by 2033 | CAGR of 13.75%

The Global Gene Panel Market Size was Valued at USD 1.23 Billion in 2023 and the Worldwide Gene Panel Market…

Global Cancer Biomarkers Market to Surge from USD 22.78 Billion in 2023 to USD 82.66 Billion by 2033, Achieving a CAGR of 13.76%

According to a research report published by Exactitude Consultancy, Companies covered:Abbott Laboratories Inc. - North America, Agilent Technologies Inc. -…

Myriad Genetics to Participate in Two Upcoming Investor Healthcare Conferences

SALT LAKE CITY, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic…

Myriad Genetics, Inc. (MYGN) Q2 2024 Earnings Call Transcript

…

Myriad Genetics (MYGN) Q2 Earnings Surpass, 24 Outlook Raised

Myriad Genetics (MYGN) delivers a strong performance across its portfolio in the second quarter of 2024 and increases its long-term…

Myriad Genetics (MYGN) Expands in MRD Testing With New Collab

Myriad Genetics (MYGN) inks an agreement with Personalis to cross-license patent estates covering tumor-informed approaches to detect minimal residual disease.…

Myriad Genetics (MYGN) Advances in MRD Space With New Patent

Myriad Genetics (MYGN) achieves a second foundational patent bolstering the MRD assay development.…

Global PCOS Diagnostic Market Size To Exceed USD 6.1 Billion By 2033 | CAGR Of 5.18%

The Global PCOS Diagnostic Market Size was Valued at USD 3.68 Billion in 2023 and the Worldwide PCOS Diagnostic Market…

Global Companion Diagnostics Market Size To Exceed USD 23.12 Billion By 2033 | CAGR Of 12.50%

The Global Companion Diagnostics Market Size was Valued at USD 7.12 Billion in 2023 and the Worldwide Companion Diagnostics Market…

Myriad Genetics (MYGN) and GSK Unite to Boost HRD Testing

Myriad Genetics (MYGN) collaborates with GSK to improve access to HRD diagnostic testing for HGSOC patients.…

Myriad Genetics (MYGN) Banks on Innovation Amid Macro Woes

Myriad Genetics (MYGN) continues to enhance its customer targeting, digital marketing and overall operating model to drive commercial leverage in…

QIAGEN and Myriad Genetics develop distributable homologous recombination deficiency test for global research and companion diagnostics applications

VENLO, The Netherlands and SALT LAKE CITY, May 30, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime…

dpa-AFX ProFeed